

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer

M Ikeda¹, S Okada^{*1}, K Tokuuye², H Ueno¹ and T Okusaka¹

¹Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; ²Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan

This study investigated the maximum-tolerated dose of gemcitabine based on the frequency of dose-limiting toxicities of weekly gemcitabine treatment with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Fifteen patients with locally advanced pancreatic cancer that was histologically confirmed as adenocarcinoma were enrolled in this phase I trial of weekly gemcitabine (150–350 mg m⁻²) with concurrent radiotherapy (50.4 Gy in 28 fractions). Gemcitabine was administered weekly as an intravenous 30-min infusion before radiotherapy for 6 weeks. Three of six patients at the dose of 350 mg m⁻² of gemcitabine demonstrated dose-limiting toxicities involving neutropenia/ leukocytopenia and elevated transaminase, while nine patients at doses of 150 mg m⁻² and 250 mg m⁻² did not demonstrate any sign of dose-limiting toxicity. Of all 15 enrolled patients, six patients (40.0%) showed a partial response. More than 50% reduction of serum carbohydrate antigen 19-9 level was observed in 13 (92.9%) of 14 patients who had pretreatment carbohydrate antigen 19-9 levels of 100 U ml⁻¹ or greater. The maximum-tolerated dose of weekly gemcitabine with concurrent radiotherapy was 250 mg m⁻², and this regimen may have substantial antitumour activity for patients with locally advanced pancreatic cancer. A phase II trial of weekly gemcitabine at the dose of 250 mg m⁻² with concurrent radiation in patients with locally advanced pancreatic cancer is now underway.

British Journal of Cancer (2002) 86, 1551–1554. DOI: 10.1038/sj/bjc/6600256 www.bjcancer.com
© 2002 Cancer Research UK

Keywords: pancreatic cancer; gemcitabine; chemoradiotherapy; CA19-9

Pancreatic cancer (PC) is diagnosed at an advanced stage in most patients, despite recent improvements in diagnostic techniques. Among these patients, roughly half are diagnosed with locally advanced disease radiographically confined to the pancreas and surrounding tissues (Okada, 1999). In the patients with locally advanced PC, prospective randomized trials conducted by Moertel *et al* (1969) and the Gastrointestinal Tumor Study Group (GITSG) (Moertel *et al*, 1982; Gastrointestinal Tumor Study Group, 1988) have demonstrated that the combination of radiotherapy and chemotherapy (chemoradiotherapy; CRT) resulted in significantly better survival than either radiotherapy alone or chemotherapy alone. In patients with resectable PC, the randomised controlled trial conducted by GITSG demonstrated a significant survival advantage for patients receiving adjuvant CRT (Gastrointestinal Tumor Study Group, 1987), but the European Study Group for Pancreatic Cancer (ESPAC) trial failed to show the survival benefit of adjuvant CRT (Neoptolemos *et al*, 2001). Thus, CRT is presently accepted as the standard treatment for locally advanced PC (Okada, 1999), but the role of adjuvant CRT for patients with resectable PC remains controversial. However, optimal CRT regimens have not yet been determined, although various anticancer agents and radiation schedules are being examined in clinical trials.

Gemcitabine is a novel deoxycytidine analogue with a broad spectrum of antitumour activity against a variety of solid tumours

including PC (Abratt *et al*, 1994; Casper *et al*, 1994). In patients with advanced PC, gemcitabine demonstrated a greater clinical benefit and survival compared with 5-fluorouracil (Bruis *et al*, 1997). Gemcitabine has also been shown to be a potent radiosensitizer in human pancreatic and other solid tumour cell lines (Lawrence *et al*, 1996; Shewach and Lawrence, 1996; van Putten *et al*, 2001), suggesting that the combination of radiotherapy and gemcitabine may improve survival in patients with locally advanced PC. Therefore, we conducted a phase I trial to determine the maximum-tolerated dose (MTD) of gemcitabine based on the frequency of dose-limiting toxicities (DLT) of weekly gemcitabine treatment with concurrent radiotherapy in patients with locally advanced PC.

PATIENTS AND METHODS

Eligibility

Patients eligible for study entry had histologically or cytologically confirmed locally advanced nonresectable PC. Eligibility criteria were: 20–74 years of age; Karnofsky performance status of 50–100 points; no evidence of distant metastasis, measurable or assessable disease, an estimated life expectancy ≥ 8 weeks after study entry; no prior treatment for PC; adequate haematological function (haemoglobin ≥ 10 g dl⁻¹, leukocytes ≥ 4000 mm³, neutrophils > 2000 mm³, and platelets $\geq 100\,000$ mm³), adequate hepatic function (serum total bilirubin ≤ 2.0 mg dl⁻¹ and serum transaminases (glutamic oxaloacetic transaminase (GOT)/glutamic pyruvic transaminase (GPT)) ≤ 2.5 times upper normal limit

*Correspondence: Dr S Okada; E-mail: address: sokada@ncc.go.jp
Received 20 September 2001; revised 21 January 2002; accepted 25 February 2002

(UNL)), and adequate renal function (serum creatinine within normal limit); written informed consent.

The exclusion criteria were as follows: active infection; severe heart disease; interstitial pneumonitis or pulmonary fibrosis; pleural effusion or ascites; active gastroduodenal ulcer; severe mental disorder, active concomitant malignancy; pregnant and lactating females; females of childbearing age unless using effective contraception; other serious medical conditions.

Ultrasonography, computed tomography of the abdomen, and chest X-ray were performed as pretreatment staging to assess the local extension of the tumour and exclude the presence of distant metastasis. The criteria of computed tomography for the nonresectability of the tumour included tumour encasement of the celiac trunk and/or superior mesenteric artery, and obstruction or bilateral invasion of the portal vein. All patients with obstructive jaundice underwent percutaneous transhepatic or endoscopic retrograde biliary drainage before CRT.

Treatment schedule

Radiation therapy was delivered through four fields as a single course of 50.4 gray (Gy) in 28 fractions over 5.5 weeks, using 10–14 megavolt photons (MM22, Scanditronix, Uppsala, Sweden). The radiation field included the primary tumour and a margin of 1–3 cm covering the regional lymph nodes, and was defined by treatment-planning computed tomography (GE9800, GE Medical Systems, Milwaukee, WI, USA) obtained 1 or 2 days before initiation of CRT. Lateral treatments were administered together with anteroposterior:posteroanterior (AP:PA) fields so that radiation to the spinal cord could be limited to 40 Gy.

Gemcitabine was administered intravenously over 30 min starting 2 h before radiotherapy weekly for 6 weeks. The scheduled dose of gemcitabine was initially 350 mg m⁻² per week. However, because of excessive toxicity at this initial dose level, the treatment plan was revised to include lower dose levels of 150 and 250 mg m⁻² per week. Prophylactic antiemetics were not administered. However, in patients who experienced grade 2 or higher nausea/vomiting, antiemetics including granisetron (Kytril; SmithKline Beecham, Philadelphia, PA, USA) were permitted during subsequent administration of gemcitabine.

Patient cohorts had a minimum of three patients at each dose level. If no DLT was observed in the initial three patients, the dosage was escalated in successive cohorts. If DLT was observed in one or two of the initial three patients, three additional patients were evaluated at that dose level. If only one or two of six patients experienced DLT, dose escalation would continue. However, if three or more patients experienced DLT at a given dose level, then the previous dose level would be considered MTD. DLT was defined as the following manifestations of toxicity observed during CRT or within 2 weeks after completing CRT: grade 3 leukocytopenia and/or neutropenia with high fever, grade 4 haematological toxicities, serum creatinine of ≥ 2.0 times UNL, total bilirubin level of ≥ 5.0 times UNL, serum GOT/GPT of ≥ 10 times UNL, grade 3 or 4 non-haematological toxicities (excluding nausea, vomiting, anorexia, fatigue, constipation, alopecia, and dehydration), two successive weeks' omission of the administration of gemcitabine owing to any toxicity, or treatment periods exceeding 8 weeks.

When DLT or tumour progression was observed during CRT, CRT was stopped. When grade 3 haematological toxicity, serum creatinine of 1.5–2.0 times UNL, total bilirubin level of 3.0–5.0 times UNL, serum GOT/GPT of 5.0–10 times UNL, and/or grade 2 non-haematological toxicity (excluding nausea, vomiting, anorexia, fatigue, constipation, alopecia, and dehydration) were observed, gemcitabine administration was omitted and postponed to the next scheduled treatment day. The radiotherapy was also suspended, and then resumed when toxicities recovered.

Toxicity and response evaluation

The primary end-point of this trial was to evaluate the frequency of DLT, and the secondary end-point was to evaluate the potential antitumour activity. Treatment related toxicities were assessed using National Cancer Institute – Common Toxicity Criteria version 2.0. During CRT, complete blood count with differential, serum chemistry, and urinalysis were measured at least once a week. Tumour response was evaluated at the completion of CRT and thereafter every 8 weeks until tumour progression, according to the standard World Health Organization criteria (Miller *et al*, 1981). Serum carcinoembryonic antigen levels (CEA) and serum carbohydrate antigen 19-9 levels (CA19-9) were measured monthly by an immunoradiometric assay. This phase I study was approved by the Institutional Review Board of the National Cancer Center.

RESULTS

Patients characteristics

Fifteen patients were enrolled in this study from May 2000 to April 2001 at the National Cancer Center Hospital, Tokyo, Japan. The characteristics of the patients are listed in Table 1. The median age was 59 (range: 51–74) years. Karnofsky performance status was 100 in one patient (7%), 90 in 13 (87%), and 80 in 1 (7%). The median serum CA19-9 level is 1109 (range: 6–16780). Patients were treated with radiation and concurrent weekly gemcitabine over three dose levels, as listed in Table 2.

Toxicity

The toxicities observed in the 15 enrolled patients are listed in Table 3. There was no treatment-related death during this study. Three of six patients treated at the gemcitabine 350 mg m⁻² dose level experienced DLT; one patient developed grade 4 leukocytopenia/neutropenia, a second developed grade 4 serum GPT increase, and a third required two successive weeks' omission of gemcitabine administration due to serum GOT and GPT increase. Moreover, before DLT was observed in level 1, 8 of 31 planned administrations were omitted due to adverse effects including leukocytopenia, neutropenia, GOT/GPT increase, and severe fatigue. Because the DLTs were observed in three of six patients at the first dose level (350 mg m⁻²), the protocol was revised and subsequent patients were enrolled at lower dose levels (gemcitabine dose level –1: 150 mg m⁻², level 0: 250 mg m⁻²). Six patients were enrolled in level 0 to evaluate the frequency of DLT more accurately, although no DLT was observed in the initial three patients. One of 18 planned administrations at level –1 and 4 of 36 administrations at level 0 were omitted due to adverse effects, including grade 3 leukocytopenia, grade 3 neutropenia, grade 3 thrombocytopenia, and grade 3 GOT/GPT increase which did not exceed 10 times UNL. However, these toxicities were mild and transient, and all patients treated at level –1 or level 0 completed the scheduled course of CRT without DLT. Gastric ulcer with epigastralgia was observed in one patient (level 0) 1 week after CRT, but the patient recovered with medical treatment using omeprazole (Omepral; Astra Zeneca, Sweden). Thus, weekly gemcitabine at a 150 mg m⁻² or a 250 mg m⁻² dose was considered well tolerated.

Response

Six patients (level 1: 4 patients, level –1: 0 patients, level 0: 2 patients) achieved partial response, giving an overall response rate of 40.0% (95% confidence interval, 15.2–64.8%), and the mean duration of response was 7.5 months (range: 3.3–12.3 months). The remaining nine patients demonstrated stable disease. After the completion of CRT, the serum CA19-9 level was reduced more than 50% in 13 (92.9%) of 14 patients who had shown a pretreat-

Table 1 Patient characteristics

Characteristics		Number of patients (%)
Age (years)	median (range)	59 (51–74)
Gender	male	10 (67%)
	female	5 (33%)
Karnofsky performance status	100	1 (7%)
	90	13 (87%)
	80	1 (7%)
Tumour location	head	3 (20%)
	body-tail	12 (80%)
CEA (ng ml ⁻¹)	median (range)	4.7 (1.2–98.3)
CA19-9 (U ml ⁻¹)	median (range)	1109 (6–16780)

CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9.

Table 2 Dose schedules of weekly gemcitabine with concurrent radiotherapy

Dosage level	Gemcitabine dose (mg m ⁻²)*	Number of patients
– I	150	3
0	250	6
I	350	6

*Intravenous infusion over 30 min weekly for 6 weeks.

Table 3 Toxicity of weekly gemcitabine with concurrent radiotherapy

Grade	Level – I (n=3)			Level 0 (n=6)			Level I (n=6)		
	1,2	3	4	1,2	3	4	1,2	3	4
Haemoglobin	3	0	0	5	1	0	3	0	0
Leukocytes	2	1	0	2	4	0	2	3	1
Neutrophils	1	1	0	3	1	0	3	2	1
Platelets	4	0	0	2	2	0	3	0	0
Anorexia	1	2	0	4	2	0	2	2	1
Nausea	2	0	0	4	2	0	4	1	0
Vomiting	1	0	0	4	0	0	5	0	0
Diarhoea	0	0	0	0	0	0	5	0	0
Fatigue	3	0	0	6	0	0	5	0	0
Gastric ulcer	0	0	0	1	0	0	0	0	0
Total Bilirubin	2	0	0	3	0	0	2	0	0
GOT	2	0	0	3	1	0	1	2	0
GPT	2	0	0	2	3	0	1	1	1
Alkaline phosphatase	2	0	0	3	0	0	2	0	0

ment level of 100 U ml⁻¹ or greater, and the serum CEA level was reduced more than 50% in four (80.0%) of five patients who had a pretreatment level of 10 ng ml⁻¹ or greater (Table 4).

DISCUSSION

Currently, concomitant external beam radiotherapy and chemotherapy has been accepted as the standard therapy for patients with locally advanced nonresectable PC (Okada, 1999), because randomized trials have demonstrated improved survival with CRT compared with that by either radiation alone or chemotherapy alone (Moertel *et al*, 1969, 1981; Gastrointestinal Tumor Study Group, 1988), although the role of adjuvant CRT for patients with resectable PC remains controversial. To intensify the treatment efficacy, various anticancer agents, and radiation schedules are being examined in clinical trials. However, to date, optimal CRT regimens have not yet been determined.

Table 4 Therapeutic effects of weekly gemcitabine with concurrent radiotherapy

Level	Case	Tumour response (duration of response)	CEA (ng ml ⁻¹)		CA19-9 (U ml ⁻¹)	
			Before ^a	After ^b	Before ^a	After ^b
I	1	NC	1.7	1.0	160	710
	2	PR (6.0 mo)	11.1	2.7	10740	3718
	3	PR (7.7 mo)	1.2	0.7	366	36
	4	PR (12.3+mo)	14.5	3.5	7110	82
	5	PR (11.9+mo)	3.9	3.4	569	9
	6	NC	63.4	1.7	16780	313
– I	7	NC	7.2	2.9	908	81
	8	NC	1.8	2.4	6	4
	9	NC	3.4	3.5	377	90
0	10	NC	3.3	3.0	1349	461
	11	NC	9	4.4	101	18
	12	NC	4.7	3.5	8580	960
	13	PR (3.3+mo)	4	3.3	1109	410
	14	PR (3.6+mo)	98.3	14.6	6160	406
	15	NC	97.1	50.8	7680	2640

CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; NC: no change; PR: partial response; mo: months. ^aMaximal levels before treatment. ^bMinimal levels after treatment.

Gemcitabine produced significantly better clinical benefit (decreased pain, improved performance status and/or weight gain) (response rate, 23.8% vs 4.8%) and survival advantage (median survival, 5.6 vs 4.4 months) compared with bolus 5-fluorouracil in a phase III trial (Burris *et al*, 1997), and the similar effects on disease-related symptoms were documented in patients with 5-fluorouracil-refractory PC (Rothenberg *et al*, 1996). Moreover, in over 3000 patients with advanced PC treated with gemcitabine, notable disease-related symptom improvement (response rate, 18.4%) and survival (median survival, 4.8 months) were also seen (Storniolo *et al*, 1999). Therefore, gemcitabine has recently been accepted as the first-line chemotherapy for advanced PC, particularly in Western countries. In the majority of reported clinical trials including these trials, gemcitabine was administered once weekly. Gemcitabine has also been demonstrated *in vitro* and *in vivo* to enhance the cytotoxic activity of radiation (Lawrence *et al*, 1996; Shewach and Lawrence, 1996), although the precise mechanism of radiosensitization remains unknown (van Putten *et al*, 2001). Some clinical trials of gemcitabine and concurrent radiotherapy have been reported (Blackstock *et al*, 1999; Talamonti *et al*, 2000), but the optimal dosage for a weekly gemcitabine schedule has not yet been elucidated. Although it has been reported that a twice-weekly schedule of gemcitabine is superior to a once-weekly schedule of gemcitabine for radiosensitization (Blackstock *et al*, 1999), the dose of gemcitabine was much lower (40 mg m⁻², twice-weekly) than that used for systemic chemotherapy. In patients with locally advanced PC treated with CRT, it is important to enhance the local control and simultaneously reduce the risk of distant metastases. Therefore, this phase I trial was designed to determine the MTD of weekly gemcitabine with concurrent radiation in patients with locally advanced PC. Eligibility criteria of this trial included Karnofsky performance status of 50–100 points. However, all enrolled patients had the Karnofsky performance status of 80 or above, because the patients with poor performance status (e.g. Karnofsky performance status of less than 70) were considered to be intolerable to CRT for fear of the treatment-related toxicities such as fatigue.

We expected that the dose of weekly gemcitabine with concurrent radiotherapy would be close to 1000 mg m⁻², which is the standard dose for weekly gemcitabine administration for PC. However, DLTs involving neutropenia/leukocytopenia and elevated transaminase were observed in three of six patients at the first dose level (350 mg m⁻²), and the protocol was therefore revised to

include lower dose levels (150 and 250 mg m⁻² per week). All nine patients treated at the dose of 150 or 250 mg m⁻² per week of gemcitabine completed the scheduled course of CRT without DLT. In this CRT, the most common toxicities were leukocytopenia and/or neutropenia. However, these toxicities were mild and transient at level -1 and level 0, and all patients recovered within a week without any specific treatment for these toxicities. Anorexia and/or nausea observed on the day of gemcitabine administration were the major non-haematological toxicities. However, these toxicities were relieved by prophylactic use of granisetron on subsequent administration of gemcitabine. Serum GOT/GPT increase observed at level 0 (250 mg m⁻²), which was another major non-haematological toxicity, was also mild and transient. Therefore, weekly gemcitabine at a dose of 150 mg m⁻² or 250 mg m⁻² was considered well tolerated, and the MTD was determined to be 250 mg m⁻².

With regard to antitumour activity of weekly gemcitabine with concurrent radiation, 6 out of 15 patients achieved partial response,

giving an overall response rate of 40.0% (95% confidence interval, 15.2–64.8%). Moreover, the serum CA19-9 level was reduced more than 50% after the completion of CRT in 13 (92.9%) of 14 patients with a pretreatment level of 100 U ml⁻¹ or greater. These results are favourable compared with those of patients treated with CRT at other treatment schedules (Moertel *et al*, 1969, 1981; Gastrointestinal Tumor Study Group, 1988; Ishii *et al*, 1997; Blackstock *et al*, 1999; Talamonti *et al*, 2000; Okusaka *et al*, 2001). To date, however, there are no data on overall survival and progression-free survival because of the short follow-up periods. Phase II trial is required to clarify the antitumour activity and the effect of weekly gemcitabine with concurrent radiation on survival.

In conclusion, the MTD of weekly gemcitabine with concurrent radiotherapy was 250 mg m⁻², and this regimen may have substantial antitumour activity for patients with locally advanced PC. A phase II trial of weekly gemcitabine at a dose of 250 mg m⁻² with concurrent radiation in patients with locally advanced PC is now underway.

REFERENCES

- Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. *J Clin Oncol* **12**: 1535–1540
- Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. *J Clin Oncol* **17**: 2208–2212
- Bruiss III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff YDD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* **15**: 2403–2413
- Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. *Invest New Drugs* **12**: 29–34
- Gastrointestinal Tumor Study Group, (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. *Cancer* **59**: 2006–2010
- Gastrointestinal Tumor Study Group, (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. *J Natl Cancer Inst* **80**: 751–755
- Ishii H, Okada S, Tokuyue K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H (1997) Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. *Cancer* **79**: 1516–1520
- Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. *Int J Radiat Oncol Bio Phys* **34**: 867–872
- Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. *Cancer* **47**: 207–214
- Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. *Lancet* **2**: 865–867
- Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Rammung K, Douglas Jr HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1982) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. *Cancer* **48**: 1705–1710
- Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaïne F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* **358**: 1576–1585
- Okada S (1999) Non-surgical treatments of pancreatic cancer. *Int J Clin Oncol* **4**: 257–266
- Okusaka T, Okada S, Tokuyue K, Wakasugi H, Saisho H, Ishikawa O, Matsuno S, Sato T, Sato K (2001) Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. *Cancer* **91**: 1384–1389
- Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. *Ann Oncol* **7**: 347–353
- Shewach DS, Lawrence TS (1996) Gemcitabine and radiosensitization in human tumor cells. *Invest New Drugs* **14**: 257–263
- Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. *Cancer* **85**: 1261–1268
- Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson III AB (2000) Eastern cooperative oncology group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. *J Clin Oncol* **18**: 3384–3389
- van Putten JWG, Groen HJM, Smid K, Peters GJ, Kampinga HH (2001) End-joining deficiency and radiosensitization induced by gemcitabine. *Cancer Res* **61**: 1585–1591